跳至主要内容
临床试验/NCT01969630
NCT01969630Unknown4 期

Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions

Ospedale San Donato2 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
4 期
入组人数
250
试验地点
2
主要终点
angiographic binary restenosis

研究概览

简要总结

To determine in patients with symptomatic femoropopliteal lesions whether percutaneous revascularization with paclitaxel-eluting balloon angioplasty (PEB) and provisional nitinol stent is superior with respect to the 12-month incidence of restenosis compared to treatment with systematic paclitaxel-eluting stent (PES) angioplasty

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • intermittent claudication or critical limb ischemia
  • de novo stenosis ≥ 50% or occlusion of at least 40 mm in length located in femoropopliteal arteries
  • presence of a clear healthy segment between the lesion in superficial femoral and common femoral artery and between popliteal and tibioperoneal trunk
  • presence of at least 1 patent tibial vessel with distal run-off (below-the-knee artery was considered patent if free from obstructive lesions determining angiographic stenosis >70%)

排除标准

  • life expectancy <1 year
  • contraindication for combined antiplatelet therapy or known allergy to nickel or paclitaxel
  • need for major amputation (MA) at the time of enrolment
  • Failure to recanalize intended below-the-knee arteries in CLI patients at risk of major amputation

结局指标

主要结局

angiographic binary restenosis

时间窗: 12 months

incidence of binary restenosis

次要结局

  • Composite of all cause mortality, major amputation and target lesion revascularization.(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Leonardo Bolognese, MD

Director

Ospedale San Donato

研究点 (2)

Loading locations...

相似试验